Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 5/20 | 0.42 |
| ▸ | LIG1 | P18858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071237 | 0.83 | NPSR1 (0.46) | KDM1ARCOR1LIG1MEN1KMT2A | |
| SCHEMBL10071236 | 0.83 | MEN1 (0.47) | KDM1ARCOR1LIG1CYP2C9MEN1 | |
| SCHEMBL10071225 | 0.82 | KDM1A (0.50) | KDM1AMEN1KMT2ACYP2C19 | |
| SCHEMBL10071234 | 0.80 | HSD11B1 (0.38) | MEN1KMT2A | |
| SCHEMBL13884396 | 0.73 | LIG1 (0.41) | KDM1ARCOR1LIG1HSD17B10CYP3A4 | |
| SCHEMBL10071239 | 0.73 | LMNA (0.51) | KDM1ATSHRMEN1KMT2A | |
| SCHEMBL20149044 | 0.73 | KDM1A (0.53) | KDM1ARCOR1LIG1HSD17B10TSHR | |
| SCHEMBL12860013 | 0.72 | LIG1 (0.40) | KDM1ARCOR1LIG1MEN1KMT2A | |
| SCHEMBL10071228 | 0.72 | KMT2A (0.50) | TSHRMEN1KMT2ACYP2C19 | |
| SCHEMBL4772628 | 0.72 | KDM1A (0.49) | KDM1ARCOR1LIG1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | PPOX, IDH3A, HMOX2 | KDM1A 1406/4885RCOR1 1859/4885LIG1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.